JaLCDOI 10.18926/AMO/56254
フルテキストURL 72_5_535.pdf
著者 Sato, Daisuke| Gohda, Tomohito| Kihara, Masao| Kanaguchi, Yasuhiko| Kobayashi, Takashi| Mano, Satoshi| Sasaki, Yu| Nohara, Nao| Murakoshi, Maki| Nakata, Junichiro| Suzuki, Hitoshi| Ueda, Seiji| Horikoshi, Satoshi| Suzuki, Yusuke|
抄録 Some patients with chronic kidney disease (CKD) receiving hemodialysis develop erythropoietin-resistant anemia, possibly due to zinc deficiency. The frequency of zinc deficiency in CKD (stages 1-5 and 5D) and CKD improvement via zinc supplementation are not completely verified. Here 500 CKD patients (Stage 1/2, n=100; Stage 3, n=100; Stage 4, n=100, Stage n=5, 100; Stage 5D, n=100) will be recruited to determine the frequency of serum zinc deficiency at each CKD stage. Patients with serum zinc concentrations <80 μg/dL will be treated with zinc acetate dihydrate (NobelzinR) to evaluate its effects on hypozincemia, taste disturbances, and anemia.
キーワード zinc acetate dihydrate anemia chronic kidney disease
Amo Type Clinical Study Protocol
発行日 2018-10
出版物タイトル Acta Medica Okayama
72巻
5号
出版者 Okayama University Medical School
開始ページ 535
終了ページ 538
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30369613